$Onconetix (ONCO.US)$ $ONCO owns Proclarix® through a acquisition valued at $75 million.
Onconetix developed and plans to market Proclarix in the U.S. with LabCorp deal
For example, LabCorp acquired Personal Genome Diagnostics (PGDx) for $450 million
Onconetix also secured FDA approval for ENTADFI
Recent compliance with NASDAQ, post R/S June 13, 2025....From filings 7 days ago

$Onconetix (ONCO.US)$ $ONCO NASDAQ hearings panel has decided to allow ONCO to remain listed👀
The upcoming deal with Ocuvex, brings an FDA-approved product, Omlonti®, along with late-stage clinical assets
Onconetix currently owns Proclarix®, approved in the EU, and FDA approved ENTADFI
Post R/S🔥